Monday, July 9, 2007
Alnylam in Transformative Deal with Roche
Roche may use this license to discover and develop RNAi Therapeutics in four out of 20 Alnylam defined therapeutic focus areas: oncology, respiratory, metabolic disease, and non-viral liver diseases. This excludes, however, gene targets that have already been exclusively licensed to other 3rd party licensees or are covered by Alnylam’s own gene-target specific IP. Further reasonable milestone payments could top $1billion with additional royalties on any product sales.
This landmark agreement could significantly speed up the whole field of RNAi Therapeutics by bringing into the fold a highly resourceful biopharmaceutical company with a proven track-record in bringing innovative medicines to patients (see Roche’s Genentech alliance). Moreover, Alnylam, which has a promising RNAi Therapeutics candidate for RSV in phase II clinical trials, will now have all the financial resources it needs to greatly expand and accelerate its own proprietary pipeline and may never need to raise cash through dilutive secondary offerings. What is more, similar deals could follow as Alnylam is free to issue similar non-exclusive licenses, including in the 4 fields covered today, for similar, if not better conditions. The interest should only increase as more partnerships are being announced and players still outside of Alnylam’s umbrella IP estate may now rush to become licensed before their competitors will claim some valuable gene targets of interest.
In light of this, Alnylam’s share price which shot up over 50% today should have much room to extend its rally. Today’s closing price of $23.12, giving the company a market capitalisation of around $900M with over $500M in cash or cash equivalents, could easily be seen as a very attractive bargain. Still below its all-time high set in the wake of Merck’s acquisition of Sirna Therapeutics last year for $1.1billion, it would not be surprising to see the stock extend its rally considerably as the wider financial community comes to grasp with the magnitude of today’s events.
I congratulate John Maraganore and his team at Alnylam for today’s accomplishment. This astounding deal gives me time to pause and rethink my long-held dogma that turning the promise of RNAi Therapeutics into reality is a largely science-driven endeavour. What we have witnessed today will bring some hope into the lives of many patients and relatives suffering from a range of serious diseases. It may not be this, the next, or even the year thereafter, but possibly sooner rather than later.
Disclaimer: This blog is not intended for distribution to or use by any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject the author or any of his collaborators and contributors to any registration or licensing requirement within such jurisdiction. This blog expresses only my opinions, they may be flawed and are for entertainment purposes only. Opinions expressed are a direct result of information which may or may not be accurate, and I do not assume any responsibility for material errors or to provide updates should circumstances change. Opinions expressed in this blog may have been disseminated before to others. This blog should not be taken as investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investments particularly in the field of RNAi Therapeutics and biotechnology carry a high risk of total loss. You, the reader must make your own investment decisions in consultation with your professional advisors in light of your specific circumstances. I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog.